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A r t i c l e s
Billions of apoptotic cells are generated each day in the body's tissues, and the rapid clearance of these dead cells is essential for both tissue homeostasis and resolution of the inflammatory response to infection. Inefficient clearance can lead to tissue damage and the development of autoimmunity 1 . However, the mechanisms responsible for the clearance of apoptotic cells in inflammatory settings versus homeostatic settings are unknown. We sought to determine whether individual members of the TAM family of receptor tyrosine kinases (RTKs)-TYRO3, Axl and Mer 2 -might be specialized to function in these very different environments.
The TAM RTKs are known to regulate the innate immune response [3] [4] [5] , mediate the homeostatic phagocytosis of apoptotic cells and membranes in adult tissues [6] [7] [8] [9] , facilitate the infection of target cells by enveloped viruses 10, 11 and contribute to the progression and metastasis of human cancers [12] [13] [14] . However, the specific roles of individual TAM receptors, together with their ligands GAS-6 and protein S, are poorly understood.
Genetic studies have shown that TAM signaling has an especially important role in sentinel cells of the immune system 3, 4 , where the principal TAM receptors are Axl and Mer. Activation of either Mer or Axl in these cells has been found to dampen activation of the immune system 3 , and the upregulation and activation of Axl in dendritic cells (DCs) is an intrinsic negative feedback inhibitor of the innate immune response 5, 15 . Accordingly, deficiencies in TAM signaling result in profound autoimmunity 3, 4 .
We found that Axl and Mer were dedicated to function in inflammatory and tolerogenic settings, respectively. Macrophage expression of Mer was upregulated by immunosuppressive agents such as dexamethasone (Dex), whereas Axl was inhibited by such agents. Conversely, proinflammatory agents upregulated expression of Axl and inhibited expression of Mer. We found that Mer and Axl specifically mediated the phagocytosis of apoptotic cells in homeostatic environments and inflammatory environments, respectively, and that catalytic activation of these receptors was required for these events. Notably, this activation had to be induced by a TAM ligand whose binding bridged a phagocyte TAM receptor to the 'eat-me' signal phosphatidylserine (PtdSer) on the target apoptotic cell.
We further demonstrated a difference between Mer and Axl in their ligand dependence: both GAS-6 and protein S drove Mer-dependent phagocytosis, but only GAS-6 was able to drive Axl-dependent phagocytosis. GAS-6 was constitutively prebound to Axl in tissues in vivo without substantial activation of the receptor, and the presence of GAS-6 in these tissues was dependent on the coexpression of Axl but was independent of Mer and TYRO3. Finally, activationinduced proteolytic cleavage of the extracellular domain of Axl liberated Axl-GAS-6 complexes, which resulted in the rapid removal of both receptor and ligand from tissues. These features of TAM biology must be taken into account in the design and application of any TAM-targeted therapy.
RESULTS

Differences in the expression of Axl and Mer
We analyzed TAM expression in both mouse bone marrow-derived macrophages (BMDMs) and dendritic cells (BMDCs) in vitro, and in subsets of cells of the immune system in vivo. In BMDCs, prepared with the growth factor GM-CSF 16 , Axl had far more abundant expression than that of Mer (Fig. 1a) . These cultures also had low expression of TYRO3. In contrast, BMDMs had abundant expression of Mer, minimal expression of Axl and no expression of TYRO3 (Fig. 1a) . The Axl mRNA copy number (per nanogram of total RNA ± s.d.) was 29 ± 4 and 28 ± 9 in BMDC cultures and BMDM cultures, respectively, which suggested that most of the difference between these cells was post-transcriptional; in contrast, for Mertk mRNA, these numbers were 3 ± 1 and 37 ± 6, respectively. Tyrosine autophosphorylation of Mer was stimulated by both protein S and GAS-6, but Axl was activated only by GAS-6 (Fig. 1b) .
In vivo, we observed several tissues in which the expression patterns of Axl and Mer paralleled those of cultured macrophages and DCs. For example, in the spleen, CD68 + tingible body macrophages were mainly Mer + (ref. 17) , whereas CD11c + white pulp DCs were mostly Axl + (ref. 18) (Supplementary Fig. 1 ). In contrast, we found that CD11c + CD11b − MHCII − cells in the lung had abundant expression of Axl but low expression of Mer (Supplementary Fig. 1 ). We also observed some populations, such as red pulp macrophages in the spleen and Kupffer cells in the liver, in which Axl and Mer were coexpressed (Supplementary Fig. 1 ). Finally, we detected divergent expression of Mer and Axl in BMDM cultures: individual BMDM cells expressed either Mer or Axl, but not both ( Supplementary  Fig. 2a, top row) .
Induction of Mer expression by tolerogenic stimuli
The differences in the expression of Axl and Mer in macrophages and DCs was matched by reciprocal responses to tolerogenic stimuli. The immunosuppressive glucocorticoid dexamethasone (Dex) has been shown to upregulate expression of Mer in human monocytederived macrophages 19 , and we found that this was also true for mouse BMDMs (Fig. 1c and Supplementary Fig. 2b ). Over a 24-hour time course, Dex mediated upregulation of the expression of Mer protein and the corresponding Mertk mRNA, and downregulation of the expression of Axl protein and Axl mRNA (Fig. 1c,d and Supplementary Fig. 2c ). As other nuclear hormones have been reported to upregulate macrophage expression of Mer 20,21 , we tested three other agonists of nuclear hormone receptors: the LXR agonist T0901317, the PPAR-δ agonist GW501516 and the PPAR-γ agonist BRL49653. Of these, only the LXR agonist potentiated Mer expression (Fig. 1e) . Although lipopolysaccharide (LPS) was a potent inducer of Axl expression in BMDMs, coincubation with Dex suppressed this effect (Fig. 1e) . Dex-mediated induction of Mer expression and suppression of Axl expression occurred at the mRNA level (Fig. 1d,f) . In addition to Dex, the related corticosteroids hydrocortisone and aldosterone also induced Mer expression in BMDMs (Supplementary Fig. 3 ).
Glucocorticoid immunosuppression is marked by changes in macrophage gene expression and the inhibition of mitogen-activated protein kinase signaling pathways 22 . As we found that upregulation of Mertk in response to Dex was faster than the induction of canonical Dex targets such as Fpr1 or Mrc1 (Supplementary Fig. 4a ), we investigated whether any of these canonical Dex effects might depend on upregulation of Mer expression or downregulation of Axl expression.
We found that Dex-mediated inhibition of LPS-induced tumornecrosis factor (TNF) (Supplementary Fig. 4b ), Dex-mediated changes in gene expression (Supplementary Fig. 4c ) and Dex inhibition of signaling via mitogen-activated protein kinases and the kinase Akt (Supplementary Fig. 4d ) were all independent of Axl and Mer.
Induction of Axl expression by inflammatory stimuli
The polarization of macrophages into a 'classically activated' M1 phenotype is stimulated by Toll-like receptor (TLR) ligands and interferon-γ (IFN-γ); their polarization into an 'alternatively activated' M2 phenotype is stimulated by interleukin 4 (IL-4) and IL-13; and their polarization into a 'regulatory-tolerogenic' phenotype is stimulated by anti-inflammatory agents 23 . We found that the expression of Axl by BMDMs was potently stimulated by inflammatory mediators of classical M1 activation, which in general had modest inhibitory effects on Mer expression. LPS, for example, elevated Axl mRNA abundance over a time course that closely followed the induction of Nos2 mRNA, which encodes inducible nitric oxide synthetase (Fig. 2a) . (There was almost no basal expression of Nos2 mRNA before stimulation (Fig. 2a) .) Over the same time course, expression of Gas6 mRNA and Pros1 mRNA, which encode GAS-6 and protein S, respectively, was modestly reduced (Fig. 2a) , as published before 24 .
We surveyed a panel of pattern-recognition receptor ligands for their ability to regulate Axl and Mer expression in BMDMs (Fig. 2b) . Axl expression was elevated by many of these inflammatory mediators, the most potent of which were ligands for TLR3, TLR4 and RIG-I, such as LPS and poly(I:C) (Fig. 2b,c) . TNF and IFN-α also elevated Axl expression (Fig. 2c) . TLR ligands induce Axl expression in DCs via type I interferons, as DCs deficient in interferon receptors fail to upregulate Axl in response to poly(I:C) 5 . Accordingly, we found that the upregulation of Axl expression by IFN-α in BMDMs was slightly faster than its upregulation by poly(I:C) (Supplementary Fig. 5 ). IFN-γ potently induced the expression of both Axl and Mer (Fig. 2c) . However, individual BMDMs in IFN-γ-treated cultures were again either Mer + or Axl + ; only a small minority of these cells coexpressed both receptors (Supplementary Fig. 2a, bottom row) .
Although the results reported above were consistent with Axl's being a marker of M1 activation, we found that IL-4 also elevated Axl expression and inhibited Mer expression in BMDMs (Fig. 2d) . As expected, these reciprocal changes in receptor expression were paralleled by reciprocal changes in the autophosphorylation of Mer and 
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Axl in response to recombinant GAS-6 (Fig. 2d ). Through analysis with surface biotinylation, we verified that Dex-mediated stimulation of Mer and LPS-mediated stimulation of Axl were both associated with increased expression of these receptors on the cell surface (Fig. 2e) . Together these observations indicated that Axl and Mer had divergent profiles of expression and regulation in inflammatory settings versus tolerogenic settings. In general, the induction of Mer expression was accompanied by the inhibition of Axl, and vice versa.
TAM specialization during phagocytosis
Genetic analyses have shown that Mer is required for the phagocytosis of apoptotic cells in various tissues 2, 6, 7, 9, 25 , but a possible role for Axl in this process has been less well studied 18, 26 . We first examined the mobilization of Axl and Mer to the surface of BMDMs in contact with apoptotic thymocytes. We labeled the apoptotic cells with a cytoplasmic dye (CellTracker Orange) and incubated them with BMDMs for 30 min. In the absence of a TAM ligand, neither Axl nor Mer was localized to the site at which the BMDM associated with the apoptotic cell (Fig. 3a,b , left). However, upon the addition of either GAS-6 or protein S to Mer + BMDMs or of GAS-6 (but not protein S) to Axl + BMDMs, we observed substantial relocalization of Mer and Axl to the membrane surrounding entrapped apoptotic cells (Fig. 3a-c) . Poly(I:C)-treated Axl + BMDMs formed a readily apparent phagocytic cup during the engulfment of apoptotic cells, as visualized by scanning electron microscopy ( Fig. 3d) .
To assess quantitatively the ability of Axl to mediate the phagocytosis of apoptotic cells, we analyzed wild-type, Axl −/− and Mertk −/− macrophages by a flow cytometry-based phagocytosis assay that exploits pHrodo 27 , a pH-sensitive fluorescent dye ( Supplementary  Fig. 6 ). We used untreated BMDM cultures and cultures treated with Dex, poly(I:C) or IFN-γ for these experiments. We found that untreated (Mer-expressing) BMDMs had a modest phagocytic index that was increased by either GAS-6 or protein S, and that the phagocytosis of apoptotic cells was Mer dependent and Axl independent (Fig. 3e) . Stimulation of phagocytosis was significantly enhanced in Dex-treated cells (Fig. 3f) . In contrast, phagocytosis by poly(I:C)-treated, Axl-expressing BMDMs was stimulated only by GAS-6, and this stimulation was entirely Axl dependent (Fig. 3g) . IFN-γ-treated BMDM cultures contained cells with high expression of either Axl or Mer ( Supplementary Fig. 2a, bottom) . Phagocytic activity in these npg A r t i c l e s cultures also was potentiated by GAS-6, and this potentiation was completely absent only in Axl −/− Mertk −/− cultures (Fig. 3i) . Together these results demonstrated that both Axl and Mer functioned as phagocytic receptors in vitro, but that they acted in different settings and relied on different ligands. Basal phagocytosis was decreased in Dex-treated cells and elevated in poly(I:C)-treated cells, and neither of these effects was TAM dependent (Fig. 3f,g ). We therefore measured changes in mRNAs encoding other known factors that mediate the recognition and engulfment of apoptotic cells in response to both pro-and anti-inflammatory stimuli. We found that many of these were coregulated with either Axl or Mer. For example, mRNA encoding the C-type lectin LOX-1 (ref. 28 ) was coregulated with Axl ( Fig. 3h) , whereas mRNA encoding the PtdSer receptor BAI1 (ref. 29 ) was coregulated with Mer (Fig. 3h) . These results indicated that activated macrophage populations and tolerogenic macrophage populations used distinct cohorts of phagocytic mediators to recognize and engulf apoptotic cells.
To assess the ability of Axl to mediate the phagocytosis of apoptotic cells by macrophages in vivo, we intraperitoneally administered pHrodo-labeled apoptotic cells 16 h after injection of poly(I:C) and allowed 1 h for phagocytosis before isolating peritoneal macrophages. CD11b + peritoneal macrophages had high expression of Axl in response to injection of poly(I:C) (Fig. 3j) . We found that poly(I:C)-treated Axl −/− macrophages phagocytized apoptotic cells less efficiently than their wild-type counterparts did (Fig. 3k) . h Expression (fold log 2 ) Supplementary  Fig. 7a,b) . Through the use of BMDCs from Tyro3 −/− mice, we found that TYRO3 was not required for Dex-induced Mer-dependent phagocytosis of apoptotic cells or for poly(I:C)-induced Axldependent phagocytosis of apoptotic cells (Supplementary Fig. 7c,d) . The minimal TYRO3 expressed by BMDCs therefore did not have a substantial role in the phagocytosis of apoptotic cells.
TAM activity during phagocytosis
We assessed the ability of apoptotic cells, in concert with TAM ligands, to modulate TAM receptor kinase activity in BMDMs. GAS-6 and protein S were produced by BMDMs (Fig. 1e) , and culture medium supplemented with 10% serum contained ~30 nM protein S. The addition of apoptotic cells to BMDMs for 30 min potentiated autophosphorylation of Axl and, to a greater extent, that of Mer (Fig. 4a) . Dex-treated cells exhibited more Mer kinase activity, which was further elevated by the addition of apoptotic cells, whereas no Axl activity was detectable (Fig. 4a) . Conversely, LPS-treated BMDMs exhibited enhanced autophosphorylation of Axl, but no activation of Mer, upon exposure to apoptotic cells (Fig. 4a) .
To control ligand concentrations in this assay, we cultured untreated BMDMs overnight in serum-free medium and washed the cells extensively before the assay. We then added low concentrations of purified ligands, 2 nM GAS-6 or 10 nM protein S, with or without the addition of apoptotic cells, and assayed the autophosphorylation of Mer and Axl. Without added GAS-6 or protein S, the presence of apoptotic cells alone had no effect on the basal kinase activity of either Mer or Axl (Fig. 4b) . The addition of GAS-6 increased the phosphorylation of Mer and, to lesser extent, that of Axl, consistent with the much higher expression of Mer than of Axl in these cultures (Fig. 4b) . The activation of Mer and Axl by GAS-6 was substantially enhanced by the inclusion of apoptotic cells (Fig. 4b) . Protein S likewise stimulated the autophosphorylation of Mer, which was also enhanced by the inclusion of apoptotic cells, but protein S had no such effect on Axl (Fig. 4b) .
To determine whether tyrosine kinase activity of the TAM receptors is required for the phagocytosis of apoptotic cells, we used BMS-777607, a small-molecule inhibitor of the Met, Ron and TAM RTKs 30 . This compound efficiently inhibits GAS-6-driven activation of both Mer and Axl in BMDCs 10 . We observed the same degree of the inhibition of TAM receptors in BMDMs (Fig. 4c) . When we added BMS-777607 to BMDMs grown under basal conditions or in the presence of Dex or poly(I:C), we found that BMS-777607 blocked phagocytosis in all settings (Fig. 4d) . Thus, Axl and Mer tyrosine kinase activities were both induced and required for TAM-dependent apoptotic cell phagocytosis.
Axl-dependent GAS-6 expression in vivo
We observed that the maintenance of GAS-6 in many tissues was entirely dependent on simultaneous expression of Axl. Although we readily detected GAS-6 by immunohistochemistry in sections of spleen, small intestine, liver and lung from wild-type mice, its expression was lost in those tissues from Axl −/− mice (Fig. 5a) . This effect was specific to Axl, as the presence of GAS-6 was unaltered in those tissues in Mertk −/− mice (Fig. 5a) and Tyro3 −/− mice (data not shown). Immunoblot analysis of GAS-6 in splenic lysates confirmed the results obtained by in vivo immunostaining (Fig. 5b) . Consistent with the hypothesis that most or all splenic GAS-6 is normally bound to Axl, we found that the basal phosphorylation of Axl was slightly higher in wild-type spleens than in Gas6 −/− splenic lysates (Fig. 5c) , but this basal Axl activation was still far below that observed upon the addition of GAS-6 in vitro (Fig. 1b) or upon the addition of activating antibody to Axl in vivo (reported below).
When we costained sections of wild-type splenic red pulp with antibody to Axl (anti-Axl) and anti-GAS-6, we observed perfect colocalization (Fig. 5d) . Similarly, when we stained poly(I:C)-treated BMDM cultures, we found that BMDMs displaying surface Axl were always the same cells that displayed surface GAS-6, and vice versa (Fig. 5e) . Specific steady-state binding of GAS-6 to Axl may have accounted for the higher basal activation of Axl than that of Mer (Fig. 4a,c) . The absence of GAS-6 in Axl −/− spleens (Fig. 5a) was not due to an inability of Axl −/− splenic macrophages to express the Gas6 gene, as we saw no difference in the Gas6 mRNA in Axl −/− spleens and wild-type spleens (Fig. 5f) . The translation of GAS-6 protein also occurred normally in Tyro3 −/− Axl −/− Mertk −/− BMDMs in culture (Fig. 1e) . Finally, the 'missing GAS-6' of Axl −/− tissues did not accumulate in the circulation, as the low concentration of GAS-6 normally present in serum was unchanged in Axl −/− mice (Fig. 5g) . Together these data indicated that maintenance of a GAS-6 protein reservoir in many tissues was dependent on the surface expression of Axl and that in these tissues GAS-6 was normally prebound to Axl. We know of no equivalent dependence for other RTKs and their ligands. 
A r t i c l e s
Antibody-mediated TAM activation RTKs are activated by ligand-driven dimerization and multimerization of receptor subunit monomers 31 . Thus, antibodies generated against RTK ectodomains often act as ligand-independent RTK activators through their ability to drive receptor dimerization 32, 33 . Although cross-activation of Mer has been achieved with a combination of primary and secondary antibodies 34 , directly activating antibodies to the TAM receptors have not yet been reported. We found that affinity-purified, polyclonal anti-Axl (AF854; R&D Systems), antiMer (AF591; R&D Systems) and anti-TYRO3 (AF759; R&D Systems) activated their respective receptors (Fig. 6a and data not shown) . In contrast to GAS-6, which activated all three TAM receptors, anti-Mer and anti-Axl displayed absolute receptor specificity (Fig. 6b) .
We assessed the utility of these antibodies as TAM activators in vivo. We first injected anti-Axl intravenously and monitored activation and expression of Axl and Mer in the spleen. We found that splenic Axl was activated within 15 min after injection and that its activity returned to baseline by 24 h (Fig. 6c) . Mer was not activated by anti-Axl, and control immunoglobulin G (IgG) had no effect on the activation or expression of Axl (Fig. 6c) . As noted before 35, 36 , we found that strong activation of Axl led to the rapid cleavage of the Axl ectodomain from the cell surface, a consequent loss of steady-state Axl, and the appearance of soluble Axl ectodomain (Fig. 6c) .
We next assessed whether varying doses of the antibodies could activate their receptors in liver, lung and spleen. We detected dosedependent activation of Axl in spleen and lung, again associated with splenic cleavage of Axl, which was especially notable at the highest antibody dose (Fig. 6d) . In the liver, cleavage of Axl was so robust that we were unable to detect any remaining Axl protein 1 h after injection of either 50 µg or 10 µg of the antibody (Fig. 6d) . We also observed dose-dependent activation of Mer in these tissues at 1 h after injection of anti-Mer (Fig. 6e) . The activation of Mer was greatest in liver and lung and, in contrast to results obtained for Axl, it was not associated with cleavage or loss of Mer protein (Fig. 6e) . These results indicated that activating antibodies functioned as specific tools for the activation of individual TAM receptors.
TAM activation alone is insufficient for phagocytosis
The TAM-activating antibodies allowed us to assess whether TAM activation in the absence of ligand could promote phagocytosis. We found that the addition of either activating antibody to Axl or activating antibody to Mer alone, in the absence of added GAS-6, had no stimulatory effect on the phagocytosis of apoptotic cells (Fig. 6f,g) . Moreover, the addition of these receptor-activating antibodies in the presence of GAS-6 actually inhibited the GAS-6-stimulated phagocytosis of apoptotic cells (Fig. 6f,g ). This inhibition could have resulted from competition between the antibody and GAS-6 for receptor binding or, for anti-Axl, antibody-induced cleavage of Axl. Thus, TAM activation was necessary for the phagocytosis of apoptotic cells by macrophages (Fig. 4d) , but activation in the absence of a tripartite receptor-ligand-apoptotic cell (PtdSer) bridging interaction 8 was not sufficient for phagocytosis.
Axl activation inhibits inflammatory responses in vivo
As the activation of Axl in DCs inhibits the production and signaling of type I interferons 5 , we hypothesized that treatment with the activating antibody to Axl, even though it did not promote phagocytosis, might be anti-inflammatory in vivo. To test this possibility, we gave mice intraperitoneal injection of LPS (or saline as a control) together with either the activating antibody to Axl or control IgG, then measured mRNAs encoding type I interferons in the spleen 2 h after injection. We observed marked suppression of Ifnb1 mRNA and Ifna4 mRNA in mice given injection of anti-Axl but not in those given injection of control IgG (Fig. 6h,i) . These results suggested that activating antibodies to Axl might be a viable approach to TAM-specific immunosuppressive therapeutics. Overall, our results WT Mertk -/-GAS-6 Spleen GAS-6 GI GAS-6 Lung Fig. 8 ).
DISCUSSION
We found that Axl and Mer segregated into distinct niches of expression and function: Mer acted mainly in settings of steady-state and induced tolerance, whereas Axl was specialized to act in the feedback inhibition of inflammation. Inflammatory stimuli that elevated Axl expression tended to decrease Mer expression, and immunosuppressive stimuli that elevated Mer tended to decrease Axl expression. Axl expression was induced in both M1-polarized macrophages and M2-polarized macrophages, which suggested that it acts as a response receptor for nearly any inflammatory insult or tissue injury. Both Axl and Mer functioned as immunosuppressive phagocytic receptors, but they operated in inflammatory environments and tolerogenic environments, respectively.
When activated by ligand binding, Axl promotes the cleavage of its extracellular domain from the cell surface through the activation of proteases 35, 36 . We found that such cleavage, which generated 'soluble Axl' , also occurred when Axl was activated by crosslinking antibodies.
Elevated soluble Axl in blood has been reported to mark multiple human disease and trauma states, including aortic aneurysm 37 , lupus flares 38 , pneumonia infection 39 , preeclampsia 40 , coronary bypass 41 and insulin resistance 42 . We suggest that cleavage of Axl and the generation of a soluble Axl-GAS-6 complex are triggered by the inflammation-induced exposure of PtdSer in these settings and may be a broadly useful diagnostic biomarker for inflammation in human disease.
Although Mer also acts to suppress inflammation 43, 44 , it does so in two settings that are very different from the inflammatory environment in which Axl operates. The first is in normal tissues that are subject to continuous cellular renewal throughout life, and in which billions of apoptotic cells are generated and cleared on a regular, often circadian, schedule 45, 46 . The second is during enhanced immunotolerance induced by corticosteroids and LXR agonists 19, 20 . We showed that the ability of these agents to stimulate phagocytosis of apoptotic cells was entirely dependent on their ability to upregulate macrophage expression of Mer.
Our data indicated that the pattern of Mer polarization in homeostatic settings and Axl polarization in inflammatory settings extended to various other phagocytic mediators. These results suggested that distinct subgroups of phagocytic receptors are specialized to A r t i c l e s orchestrate the clearance of apoptotic cells in different environments. The cleavage of Axl upon its activation suggests that Axl may be required only for initial stages of the phagocytosis of apoptotic cells. This is in agreement with work suggesting that Axl is a tethering receptor for apoptotic cells and that it acts together with CD91 (LRP-1 ('low-density lipoprotein receptor-related protein 1')) for engulfment 18 . Consistent with that suggestion, we observed that CD91 was coregulated with Axl by Dex. The segregation of Axl and Mer extended to their ligands. Unlike the other TAM receptors, Axl and GAS-6 were codependent: Axl uniquely depended on GAS-6 for its activation, and GAS-6 required Axl for its stable maintenance in vivo. The constitutive presence of an Axl-GAS-6 complex in tissues would suggest that exposure of PtdSer may be the actual trigger for Axl activation. Indeed, the low basal activity of Axl in complex with GAS-6 was substantially enhanced by exposure to PtdSer-rich membranes.
Their divergence notwithstanding, both Axl and Mer mediated the PtdSer-dependent phagocytosis of apoptotic cells, and our results have elucidated several features of the bridging model for this process 3, 8 . In this model, GAS-6 or protein S binds concomitantly a TAM receptor on the phagocyte surface and PtdSer on the apoptotic cell. First, we showed that activation of TAM kinase activity was necessary for phagocytosis, which indicated that TAM receptors serve as more than passive docking sites for apoptotic cells on the surface of phagocytes. Second, we showed that activation of TAM kinases was not sufficient for the phagocytosis of apoptotic cells. And third, we observed rapid mobilization of the receptors to sites of apoptotic cell contact upon the addition of purified ligands. Thus, the interpolation of TAM ligand between the macrophage and its phagocytic target was obligatory.
TAM receptor divergence is relevant to human therapy. TAM inhibitors are in development for cancer therapies 13, 47, 48 and the treatment of infection with enveloped viruses 10 , whereas TAM activators have been proposed as treatments for autoimmune indications 49, 50 . The fact that Mer functions on a daily basis throughout decades of adult life suggests that its long-term inhibition in the course of a cancer therapy should be evaluated for side effects, including the development of impaired vision, diminished male fertility and autoimmune disease. Long-term inhibition of Axl may result in fewer adverse reactions. In several settings, antibody-based therapies may have the advantage of absolute receptor specificity. Notably, the finding that downregulation of Axl is brought about through ectodomain cleavage calls into question the utility of the activation of Axl as a vehicle for the delivery of cytotoxic drugs in Axl-overexpressing tumors. At the same time, the use of activating antibodies to Axl-for example, in the potential treatment of lupus or arthritis flares-should have the advantage of being self-limiting owing to this receptor cleavage. Our results indicate that such antibodies may also be effective in the control of inflammation subsequent to infection. These and related considerations suggest that modulation of TAM receptors is an especially promising approach to the treatment of human disease.
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Methods and any associated references are available in the online version of the paper. 
